Human CD85d enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 10.40 pg/ml (50 μl)：14.80 pg/ml (10 μl) |
| Standard Curve Range | 312.5~20000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0345 | 0.0329 | 0.0337 | |
| 312.50 | 0.0936 | 0.0922 | 0.0929 | 0.0592 |
| 625.00 | 0.1418 | 0.1472 | 0.1445 | 0.1108 |
| 1250.00 | 0.2482 | 0.2518 | 0.2500 | 0.2163 |
| 2500.00 | 0.4908 | 0.4994 | 0.4951 | 0.4614 |
| 5000.00 | 0.9079 | 0.9281 | 0.9180 | 0.8843 |
| 10000.00 | 1.8010 | 1.8280 | 1.8145 | 1.7808 |
| 20000.00 | 3.2730 | 3.2200 | 3.2465 | 3.2128 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 278.4 | 1676.4 | 5340.2 | 335.2 | 1676.4 | 5347.2 |
| Standard Deviation | 18.3 | 50.3 | 193.0 | 17.5 | 80.8 | 160.4 |
| Coefficient of Variation(%) | 6.6 | 3.0 | 3.6 | 5.2 | 4.8 | 3.0 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human CD85d into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 80% to 127% with an overall mean recovery of 112%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (ng/ml) | Detectable (%) | Mean of Detectable (ng/ml) |
|---|---|---|---|---|
| Serum | 30 | 2.46-9.25 | 100 | 5.35 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of IL-12/IL-23 p40 in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: CD85d
The immunoglobulin-like transcript (ILT) comprise a family of activating and inhibitory type immunoreceptors whose genes are located in the same locus that encodes killer cell Ig-like receptors (KIR). ILT4, also known as LIR-2 and LILRB2, is a type I transmembrane protein expressed primarily on monocytes and dendritic cells (DC). Human ILT4 is produced as a 598 amino acid (aa) precursor including a 21 aa signal sequence, a 440 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 116 aa cytoplasmic domain. The ECD contains four Ig-like domains, and the cytoplasmic domain contains three immunoreceptor tyrosine-based inhibitory motifs (ITIM). The ECD of human ILT4 shares 76% aa identity with chimpanzee ILT4 and 74%, 81%, 33%, 52%, 77%, 61%, and 64 % aa identity with human ILT1, 2, 3, 5, 6, 7, and 8, respectively. ILT4 binds to classical MHC I proteins as well as the non-classical HLA-G1 and HLA-F molecules. It competes with CD8 alpha for MHC I binding but does not compete with KIR2DL1. Ligation of ILT4 induces Tyr phosphorylation within its cytoplasmic ITIMs, a requirement for association with SHP-1. Activation of ILT4 inhibits signaling through Fc gamma RI and Fc epsilon RI and causes DC to become tolerogenic by downregulation of costimulatory molecules. ILT4 mediates tolerogenic DC-induced CD4+ T cell energy in vitro and in vivo.
